Hypercholesterolemia News and Research

RSS
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. Too much cholesterol, however, increases a person's risk of developing heart disease.

People with hypercholesterolemia have a high risk of developing a form of heart disease called coronary artery disease. This condition occurs when excess cholesterol in the bloodstream is deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart (coronary arteries). The abnormal buildup of cholesterol forms clumps (plaque) that narrow and harden artery walls. As the clumps get bigger, they can clog the arteries and restrict the flow of blood to the heart. The buildup of plaque in coronary arteries causes a form of chest pain called angina and greatly increases a person's risk of having a heart attack.

Inherited forms of hypercholesterolemia can also cause health problems related to the buildup of excess cholesterol in other tissues. If cholesterol accumulates in tendons, it causes characteristic growths called tendon xanthomas. These growths most often affect the Achilles tendons and tendons in the hands and fingers. Yellowish cholesterol deposits under the skin of the eyelids are known as xanthelasmata. Cholesterol can also accumulate at the edges of the clear, front surface of the eye (the cornea), leading to a gray-colored ring called an arcus cornealis.
Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

USPTO awards Alnylam Notice of Allowance for patent covering methods of inhibiting expression of mutant genes

USPTO awards Alnylam Notice of Allowance for patent covering methods of inhibiting expression of mutant genes

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Lovastatin protects animals against plague

Lovastatin protects animals against plague

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent

EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Increased cholesterol levels can affect microenvironment of bone marrow

Increased cholesterol levels can affect microenvironment of bone marrow

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Pharmaceuticals announces EPO intent to grant notification for patent series covering RNAi therapeutics

Alnylam Pharmaceuticals announces EPO intent to grant notification for patent series covering RNAi therapeutics

New classification of depressive subtypes of depression proposed

New classification of depressive subtypes of depression proposed

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Novartis exercises current right to purchase 55,223 unregistered shares of Alnylam's common stock

Novartis exercises current right to purchase 55,223 unregistered shares of Alnylam's common stock

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Patients dismissed from hospital with noncardiac chest pain continue to experience cardiac events: Study

Patients dismissed from hospital with noncardiac chest pain continue to experience cardiac events: Study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.